In Reply to Hannoun-Levi et al.

Asal Rahimi; Ambrosia Simmons; D. Nathan Kim; Marilyn Leitch; Jonathan Haas; Xuejun Gu; Chul Ahn; Ang Gao; Ann Spangler; Howard E. Morgan; Sally Goudreau; Stephen Seiler; Deborah Farr; Rachel Wooldridge; Barbara Haley; Shohreh Bahrami; Sarah Neufeld; Christopher Mendez; Prasanna Alluri; Roshni Rao; Robert D. Timmerman

doi:10.1016/j.ijrobp.2022.02.034

In Reply to Hannoun-Levi et al.

Asal Rahimi, Ambrosia Simmons, D. Nathan Kim, Marilyn Leitch, Jonathan Haas, Xuejun Gu, Chul Ahn, Ang Gao, Ann Spangler, Howard E. Morgan, Sally Goudreau, Stephen Seiler, Deborah Farr, Rachel Wooldridge, Barbara Haley, Shohreh Bahrami, Sarah Neufeld, Christopher Mendez, Prasanna Alluri, Roshni RaoRobert D. Timmerman

Research output: Contribution to journal › Letter › peer-review

Original language	English (US)
Pages (from-to)	475-477
Number of pages	3
Journal	International Journal of Radiation Oncology Biology Physics
Volume	113
Issue number	2
DOIs	https://doi.org/10.1016/j.ijrobp.2022.02.034
State	Published - Jun 1 2022

ASJC Scopus subject areas

Radiation
Oncology
Radiology Nuclear Medicine and imaging
Cancer Research

Access to Document

10.1016/j.ijrobp.2022.02.034

Cite this

Rahimi, A., Simmons, A., Kim, D. N., Leitch, M., Haas, J., Gu, X., Ahn, C., Gao, A., Spangler, A., Morgan, H. E., Goudreau, S., Seiler, S., Farr, D., Wooldridge, R., Haley, B., Bahrami, S., Neufeld, S., Mendez, C., Alluri, P., ... Timmerman, R. D. (2022). In Reply to Hannoun-Levi et al. International Journal of Radiation Oncology Biology Physics, 113(2), 475-477. https://doi.org/10.1016/j.ijrobp.2022.02.034

Rahimi, A, Simmons, A, Kim, DN, Leitch, M, Haas, J, Gu, X, Ahn, C, Gao, A, Spangler, A, Morgan, HE, Goudreau, S , Seiler, S , Farr, D, Wooldridge, R, Haley, B, Bahrami, S, Neufeld, S, Mendez, C, Alluri, P, Rao, R & Timmerman, RD 2022, 'In Reply to Hannoun-Levi et al.', International Journal of Radiation Oncology Biology Physics, vol. 113, no. 2, pp. 475-477. https://doi.org/10.1016/j.ijrobp.2022.02.034

@article{1a586102ab844049946e23a2163b4eaf,

title = "In Reply to Hannoun-Levi et al.",

author = "Asal Rahimi and Ambrosia Simmons and Kim, {D. Nathan} and Marilyn Leitch and Jonathan Haas and Xuejun Gu and Chul Ahn and Ang Gao and Ann Spangler and Morgan, {Howard E.} and Sally Goudreau and Stephen Seiler and Deborah Farr and Rachel Wooldridge and Barbara Haley and Shohreh Bahrami and Sarah Neufeld and Christopher Mendez and Prasanna Alluri and Roshni Rao and Timmerman, {Robert D.}",

note = "Funding Information: This work was funded by a grant from Accuray. Funding Information: Acknowledgments: We acknowledge our clinical research team and, most importantly, our patients whom have put their trusts in us and whom have selflessly enrolled in this clinical trial to improve breast cancer treatments for the future. We thank the members of the Breast Cancer Working Group of the GEC-ESTRO (Groupe Europ{\'e}en de Curieth{\'e}rapie [GEC] and the European Society for Radiotherapy & Oncology [ESTRO]) for their thought-provoking critiques of our recently published preliminary results on single-fraction stereotactic partial breast irradiation (S-PBI). It is clear our groups both see the benefit of single-fraction accelerated partial breast irradiation (APBI) and the need for further research in this area. In this article, we respond to the issues they brought forward. This work was funded by a grant from Accuray. Disclosures: A.R. reports a grant from Accuray for this research. A.R. has given educational lectures and received honoraria from Accuray, is a consultant for Hologic, and has given educational lectures and received honoraria from Hologic. R.T. reports grants from Accuray, Varian Medical Systems, and Elekta.",

year = "2022",

month = jun,

day = "1",

doi = "10.1016/j.ijrobp.2022.02.034",

language = "English (US)",

volume = "113",

pages = "475--477",

journal = "International Journal of Radiation Oncology Biology Physics",

issn = "0360-3016",

publisher = "Elsevier Inc.",

number = "2",

}

TY - JOUR

T1 - In Reply to Hannoun-Levi et al.

AU - Rahimi, Asal

AU - Simmons, Ambrosia

AU - Kim, D. Nathan

AU - Leitch, Marilyn

AU - Haas, Jonathan

AU - Gu, Xuejun

AU - Ahn, Chul

AU - Gao, Ang

AU - Spangler, Ann

AU - Morgan, Howard E.

AU - Goudreau, Sally

AU - Seiler, Stephen

AU - Farr, Deborah

AU - Wooldridge, Rachel

AU - Haley, Barbara

AU - Bahrami, Shohreh

AU - Neufeld, Sarah

AU - Mendez, Christopher

AU - Alluri, Prasanna

AU - Rao, Roshni

AU - Timmerman, Robert D.

N1 - Funding Information: This work was funded by a grant from Accuray. Funding Information: Acknowledgments: We acknowledge our clinical research team and, most importantly, our patients whom have put their trusts in us and whom have selflessly enrolled in this clinical trial to improve breast cancer treatments for the future. We thank the members of the Breast Cancer Working Group of the GEC-ESTRO (Groupe Européen de Curiethérapie [GEC] and the European Society for Radiotherapy & Oncology [ESTRO]) for their thought-provoking critiques of our recently published preliminary results on single-fraction stereotactic partial breast irradiation (S-PBI). It is clear our groups both see the benefit of single-fraction accelerated partial breast irradiation (APBI) and the need for further research in this area. In this article, we respond to the issues they brought forward. This work was funded by a grant from Accuray. Disclosures: A.R. reports a grant from Accuray for this research. A.R. has given educational lectures and received honoraria from Accuray, is a consultant for Hologic, and has given educational lectures and received honoraria from Hologic. R.T. reports grants from Accuray, Varian Medical Systems, and Elekta.

PY - 2022/6/1

Y1 - 2022/6/1

UR - http://www.scopus.com/inward/record.url?scp=85129954700&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85129954700&partnerID=8YFLogxK

U2 - 10.1016/j.ijrobp.2022.02.034

DO - 10.1016/j.ijrobp.2022.02.034

M3 - Letter

C2 - 35569485

AN - SCOPUS:85129954700

SN - 0360-3016

VL - 113

SP - 475

EP - 477

JO - International Journal of Radiation Oncology Biology Physics

JF - International Journal of Radiation Oncology Biology Physics

IS - 2

ER -

In Reply to Hannoun-Levi et al.

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this